| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)
|
Lebellec, Loïc
|
|
2017
|
79 |
C |
p. 119-128
10 p.
|
artikel
|
| 2 |
Avoidable cancer cases in the Nordic countries – The impact of overweight and obesity
|
Andersson, Therese M.-L.
|
|
2017
|
79 |
C |
p. 106-118
13 p.
|
artikel
|
| 3 |
Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer
|
Pastorino, Ugo
|
|
2017
|
79 |
C |
p. 90-97
8 p.
|
artikel
|
| 4 |
Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial
|
Aalders, K.C.
|
|
2017
|
79 |
C |
p. 98-105
8 p.
|
artikel
|
| 5 |
Discrepancies in the use of chemotherapy and artificial nutrition near the end of life for hospitalised patients with metastatic gastric or oesophageal cancer. A countrywide, register-based study
|
Kempf, Emmanuelle
|
|
2017
|
79 |
C |
p. 31-40
10 p.
|
artikel
|
| 6 |
Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects
|
Pernot, Simon
|
|
2017
|
79 |
C |
p. 15-22
8 p.
|
artikel
|
| 7 |
Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy–Innovative Models Prolong Survival (OCTIPS) Consortium
|
Ruscito, Ilary
|
|
2017
|
79 |
C |
p. 214-225
12 p.
|
artikel
|
| 8 |
Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study
|
Gillon, Pauline
|
|
2017
|
79 |
C |
p. 226-234
9 p.
|
artikel
|
| 9 |
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
|
Bartlett, John M.S.
|
|
2017
|
79 |
C |
p. 129-138
10 p.
|
artikel
|
| 10 |
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
|
Stintzing, S.
|
|
2017
|
79 |
C |
p. 50-60
11 p.
|
artikel
|
| 11 |
Impact of detection bias on the risk of gastrointestinal cancer and its subsites in type 2 diabetes mellitus
|
de Jong, R.G.P.J.
|
|
2017
|
79 |
C |
p. 61-71
11 p.
|
artikel
|
| 12 |
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis
|
Blank, Christian U.
|
|
2017
|
79 |
C |
p. 176-184
9 p.
|
artikel
|
| 13 |
Optimal duration of adjuvant chemotherapy for high-risk node-negative (N–) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)
|
Kerbrat, Pierre
|
|
2017
|
79 |
C |
p. 166-175
10 p.
|
artikel
|
| 14 |
Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort
|
Walter, T.
|
|
2017
|
79 |
C |
p. 158-165
8 p.
|
artikel
|
| 15 |
Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer
|
Dezellus, A.
|
|
2017
|
79 |
C |
p. 72-80
9 p.
|
artikel
|
| 16 |
Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time?
|
Brighenti, Matteo
|
|
2017
|
79 |
C |
p. 149-151
3 p.
|
artikel
|
| 17 |
3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer
|
Lutz, Manfred P.
|
|
2017
|
79 |
C |
p. 41-49
9 p.
|
artikel
|
| 18 |
Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium
|
van Kampen, R.J.W.
|
|
2017
|
79 |
C |
p. 238-246
9 p.
|
artikel
|
| 19 |
Real-world data for efficient health technology assessment
|
Hall, Peter S.
|
|
2017
|
79 |
C |
p. 235-237
3 p.
|
artikel
|
| 20 |
Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre
|
Matias, Margarida
|
|
2017
|
79 |
C |
p. 185-192
8 p.
|
artikel
|
| 21 |
Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice
|
Schraa, S.J.
|
|
2017
|
79 |
C |
p. 152-157
6 p.
|
artikel
|
| 22 |
Review of phase I and II trials for Wilms' tumour – Can we optimise the search for novel agents?
|
Brok, Jesper
|
|
2017
|
79 |
C |
p. 205-213
9 p.
|
artikel
|
| 23 |
Robot-assisted laparoscopy versus laparotomy for infrarenal paraaortic lymphadenectomy in women with high-risk endometrial cancer: A randomised controlled trial
|
Salehi, Sahar
|
|
2017
|
79 |
C |
p. 81-89
9 p.
|
artikel
|
| 24 |
Squamous cell carcinoma of the pancreas: A systematic review and pooled survival analysis
|
Ntanasis-Stathopoulos, Ioannis
|
|
2017
|
79 |
C |
p. 193-204
12 p.
|
artikel
|
| 25 |
The 30-year experience—A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer
|
Desiderio, Jacopo
|
|
2017
|
79 |
C |
p. 1-14
14 p.
|
artikel
|
| 26 |
TNM classification and the need for revision of pN3a breast cancer
|
van Nijnatten, T.J.A.
|
|
2017
|
79 |
C |
p. 23-30
8 p.
|
artikel
|
| 27 |
Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer – Results from the prospective German Tumour Registry Breast Cancer cohort study
|
Schröder, Jan
|
|
2017
|
79 |
C |
p. 139-148
10 p.
|
artikel
|
Tijdschrift beschrijving